Jaro Institute of Technology Management and Research Limited
NSE: JARO | Information Technology
Market Fundamentals
Stock Intelligence & News
Jaro Institute of Technology Management and Research Ltd (544534)
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Balkrishna Namdeo Salunkhe
Read Full Analysis →Jaro Institute of Technology Management and Research Limited
Jaro Institute of Technology Management and Research Limited has informed the Exchange about Investor Presentation on Unaudited Financial Result for quarter ended June 30, 2026. |SUBJECT: General Updates
Read Full Analysis →Jaro Institute of Technology Management and Research Ltd (544534)
Investor Presentation on Unaudited Financial Results for the Quarter ended June 30, 2026.
Read Full Analysis →AI-Powered Alerts for Your Portfolio
Alerfo's AI classifies every news event by type, severity, and market impact — then instantly notifies you via Email & WhatsApp only for the stocks you track.
Jaro Institute of Technology Management and Research Limited
Jaro Institute of Technology Management and Research Limited has informed the Exchange about Copy of Newspaper Publication of the extract of Unaudited Financial Results of the quarter ended June 30, 2026. |SUBJECT: Copy of Newspaper Publication
Read Full Analysis →Jaro Institute of Technology Management and Research Limited
Jaro Institute of Technology Management and Research Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. |SUBJECT: Outcome of Board Meeting
Read Full Analysis →Jaro Institute of Technology Management and Research Limited
Financial Results |Meeting Date: 08-Aug-2026
Read Full Analysis →Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk
Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk
Read Full Analysis →Eli Lilly Shares Surge 6% On Upbeat Annual Earnings Forecast; Mounjaro Sales Spike 91%
Due to expenses associated with commercial activity during the quarter, Lilly reduced the upper end of its full-year profit expectation.
Read Full Analysis →Lilly’s revenue soars 48%, driven by demand of its GLP-1s
Lilly’s sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss.
Read Full Analysis →Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
Read Full Analysis →Get instant alerts when JARO breaks news
Join investors who track Jaro Institute of Technology Management and Research Limited on Alerfo — free plan available.
Set Free Alert →Frequently Asked Questions
What is the current trend for JARO?
JARO is currently showing a volatility profile consistent with its sector peers, with sentiment being actively monitored by Alerfo news scanners.
How can I set alerts for Jaro Institute of Technology Management and Research Limited?
You can set real-time price and news alerts by registering on the Alerfo platform and adding JARO to your custom watchlist.